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MaBioresorbable vascular scaffolds (BRS) represent a novel approach to provide transient vessel support to drug-
delivery capability without the long-term limitations of metallic drug-eluting stents (DES). The technology has the
potential to overcome many of the safety concerns associated with metallic DES and possibly even convey further
clinical beneﬁt. In particular, the BRS are designed to provide short-term lumen support, and after being completely
bioresorbed, eliminate the permanent caging typical of metallic DES. However, this technology has required new
imaging modalities and methodologies for its assessment because the design, degradation rate, loss of mechanical
property, and drug deliverability may affect its safety and efﬁcacy. We provide an overview of all existing methods
for assessing bioresorbable devices, from noninvasive to invasive, from light to sound based, and from morphological
to functional parameters. (J Am Coll Cardiol Img 2014;7:1130–48) © 2014 by the American College of Cardiology
Foundation.T he clinical introduction of bioresorbable scaf-folds (BRS) resulted in a revolutionarychange in the application of local coronary
therapies. These devices have the unique ability to
provide a temporary scaffold that is necessary to
maintain the patency of the vessel after intervention,
releasing antiproliferative drugs. The BRS then grad-
ually degrade, liberating the vessel from its cage
and permitting the restoration of vascular physiology
and integrity (1,2).
Percutaneous coronary intervention with BRS has
potential advantages over the current use of metallic
stents because after resorption, there should be no
trigger for thrombosis, thereby reducing stent/scaf-
fold thrombosis. The lack of foreign material may also
reduce the requirements for long-term dual anti-
platelet therapy and its correlated bleedingm the *Thoraxcenter, Erasmus, Rotterdam, the Netherlands; yHeart Insti
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can facilitate restoration of the vessel vasomotor
tone, adaptive shear stress, late luminal enlargement,
and late expansive remodeling. In the long term, BRS
may allow a percutaneous/surgical revascularization
of the treated segment or pharmacologically induced
plaque regression, whereas traditional stents often
preclude this option. For clinical follow-up, BRS
enable noninvasive evaluation by multislice coronary
tomography (MSCT), enabling visualization of the
vascular lumen in the treated segment without the
blooming effect observed with metallic stents.
Over the last 10 years, considerable effort has
been put forth to develop new fully bioresorbable
devices. BRS technology has gradually matured, and
there are numerous devices available for preclinical
or clinical evaluation (Table 1). However, thistute (InCor), University of São Paulo Medical School,
ascular Research Foundation, New York, New York.
reported that they have no relationships relevant to
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AB BR E V I A T I O N S
AND ACRONYM S
BRS = bioresorbable scaffolds
FF = ﬁbrofatty
FFR = fractional ﬂow reserve
ISA = incomplete scaffold
apposition
IVUS = intravascular
ultrasound
MLD = minimal lumen diameter
MPS = metallic platform stents
MSCT = multislice coronary
tomography
OCT = optical coherence
tomography
QCA = quantitative coronary
angiography
virtual histology
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1131technology has required new imaging modalities and
methodology for the assessment of BRS because
their design, degradation rate, loss of mechanical
properties, coating, and drug deliverability may
affect safety and efﬁcacy (Table 2). This review de-
scribes the imaging methods for BRS, compares BRS
with metallic stents, and describes the clinical rele-
vance of BRS.
INVASIVE QUANTITATIVE
CORONARY ANGIOGRAPHY
Invasive quantitative coronary angiography (QCA)
remains one of the most commonly used methods for
the assessment of lumen parameters for BRS. Coro-
nary restenosis is inﬂuenced by both acute gain pro-
vided by the intervention and the subsequent late
lumen loss (Figure 1). Considering the variety of BRS
under development, clear understanding of the cor-
onary restenotic mechanics is needed.SEE PAGE 1149In each patient, the treated segment (in-scaffold)
and the peri-scaffold segments (deﬁned by a length of
5 mm proximal and distal to the scaffold edge—in-
segment) should be analyzed by QCA in paired
matched angiographic views after the procedure and
at follow-up. Because these devices are radiolucent,
the only visible structures for QCA analysis are theTABLE 1 Bioresorbable Scaffolds: Materials and Current Developmen
Company Product Material
Abbott Laboratories Absorb PLLA/PDLLA
Elixir DESolve PLLA/PDLLA
Meril MeRes PLLA
Amaranth Medical FORTITUDE PLLA
ART/Terumo ART18Z PDLLA
Biotronik DREAMS Magnesium þ PLLA
Huaan XINSORB PLA/PCL/PGA
Kyoto Medical IGAKI-TAMAI PLLA
Xenogenics Ideal BioStent Polyanhydride
(ASA/adipic acid anhyd
Arterius ReBioStent Bioresorbable polymer
Cardionovum ReNATURAL Metal
Medtronic Mg Spiral Magnesium
OrbusNeich On-AVS PLLA/PDLA/TMC/eCAP
Reva Fantom Tyrosine polycarbonate
S3V Avatar Not available
Zorion Medical ZMED Magnesium þ polymer
LifeTech Lifetech Iron Stent Iron
Boston Scientiﬁc BSC BRS Magnesium
Sahajanand Sahajanand BRS PLLA?
ASA ¼ salicylic acid; BRS ¼ bioresorbable scaffolds; PCL ¼ polycaprolactone; PDLA ¼
PLA ¼ poly(lactic acid); PLLA ¼ poly-L-lactide; TMC ¼ trimethylene carbonate.metallic markers at the proximal and distal
ends of the device (Figure 2).
The following QCA parameters are computed:
minimal luminal diameter (MLD), reference
vessel diameter obtained by an interpolated
method, late loss, and binary restenosis.
LATE LOSS AND/OR LATE LUMINAL GAIN.
Late loss and/or late luminal gain are deﬁned
as the difference between MLD at post-
procedure minus MLD at follow-up. For
lumen diameter reduction, this will be a
positive number; for late increase in lumen
size, this will be a negative number. Figure 1
summarizes the lumen size changes of cur-
rent BRS tested in clinical scenarios. Please
note the unique effect of all BRS, which is the
late increase in lumen size (late gain). This
luminal gain starts when BRS start to lose
their mechanical integrity (Table 3).
ACUTE RECOIL. For acute recoil assessment, 2 spe-
ciﬁc views are analyzed. One is an image of complete
expansion of the last balloon (either the device
delivery balloon or the post-dilation balloon) at the
highest pressure. The other is a cine frame immedi-
ately after the last balloon deﬂation and the subse-
quent nitrate injection. These 2 images should be
analyzed in the same angiographic projection selected
to minimize foreshortening.
VH =t
Development Pre-Clinical Clinical Post-Clinical
✔ ✔ ✔ ✔
✔ ✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
ride)
✔ ✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔ ✔
✔
poly-D-lactide; PDLLA ¼ poly(L-lactide-co-D,L-lactide); PGA ¼ polyglycolic acid;
TABLE 2 Mechanical Properties and Degradation Rate
of Different Material Candidates for Bioresorbable
Coronary Scaffolds
Material
Tensile
Strength, MPa
Elongation,
%
Degradation
Time
Poly(L-lactide) 60–70 2–6 24 months*
Poly(DL-lactide) 45–55 2–6 12–16 months*
Poly(glycolide) 90–110 1–2 6–12 months*
50/50 DL-lactide/
glycolide
40–50 1–4 1–2 months*
82/18 L-lactide/
glycolide
60–70 2–6 12–18 months*
70/30L-lactide/
ε-aprolactone
18–22 >100 12–24 months*
Pure Fe 200 40 0.19 mm/year
Fe-35Mn alloy 430 30 0.44 mm/year
WE43 alloy 280 2 1.35 mm/year
*Degradation time depends on geometry (44,45).
MPa ¼ megapascals.
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1132Acute stent/scaffold recoil is calculated as follows.
 When a stent/scaffold delivery balloon was used
for stent/scaffold expansion, acute absolute
stent/scaffold recoil is deﬁned as the difference
between the mean diameter of the stent/scaffold
delivery balloon at the highest pressure at
implantation of stent/scaffold (X) and mean
luminal diameter of stented/scaffolded seg-
ment after implantation (Y). Absolute acute
stent/scaffold recoil is calculated as X  Y,
whereas relative acute stent/scaffold recoil is
deﬁned as (X  Y)/X and is expressed as a
percentage.
 When a post-dilation balloon was used in the
procedure, acute absolute recoil is deﬁned as
the difference between the mean diameter of
the post-dilation balloon at the highest pressure
in the post-dilated segment (X0) and mean
luminal diameter after post-dilation (Y0). Relative
acute recoil is deﬁned as (X0  Y0)/X0 and is
expressed as a percentage.
The same methodology was used throughout the
ABSORB Cohort A and Cohort B trials. The absolute
acute recoil in Absorb BVS 1.1 (Abbott Laboratories,
Abbott Park, Illinois) was 0.19  0.18 mm (6.7  6.4%),
which was not statistically different than that in BVS
1.0 (0.20  0.21 mm; 6.9  7.0%) or the metallic
everolimus-eluting stent (0.13  0.21 mm; 4.3  7.1%).
In multivariable models of the 3 pooled populations,
the balloon/artery ratio was an independent predictor
of acute recoil, whereas the type of device (scaffold or
stent) was not (3). The DESolve Nx BRS (Elixir Medi-
cal, Sunnyvale, California) and the ART stent (ART,Noisy le Roi, France) have acute recoils of 6.4  4.6%
(4) and 4.0% (data on ﬁle, ART), respectively.
CONFORMABILITY. Coronary geometry changes after
stenting might result in wall shear stress changes and
adverse events. These changes in 3-dimensional (3D)
vessel geometry are associated with decreased and
increased shear stress zones close to the stent edges.
These changes were found to be related to the
asymmetrical patterns of in-stent restenosis (5). An-
giographically, the geometric changes can be assessed
by measuring the curvature and angulation. “Curva-
ture” is deﬁned as the inﬁnitesimal rate of change in
the tangent vector at each point of the center line.
This measurement has a reciprocal relationship with
the radius of the perfect circle deﬁned by the curve
at each point. The curvature value is calculated as
1/radius of the circle in cm1 (6). “Angulation” is
deﬁned as the angle in degrees that the tip of an
intracoronary guidewire would need to reach the
distal part of a coronary bend (Figure 3) (6).
For the Absorb scaffold, from post-implantation to
follow-up, curvature increased by 8.4% (p < 0.01)
with BRS and decreased 1.9% (p ¼ 0.54) with the
metallic platform stents (MPS) (p ¼ 0.01). Angulation
increased 11.3% with BRS (p < 0.01) and 3.8% with
MPS (p ¼ 0.01); p < 0.01. From pre-implantation to
follow-up, the artery curvature decreased 3.4% with
BRS (p ¼ 0.05) and the artery angulation decreased
3.9% (p ¼ 0.16), whereas MPS presented with 26.1%
decrease in curvature (p < 0.01) and 26.9% decrease
in angulation (p < 0.01) (both p < 0.01 for the com-
parison between BRS and MPS) (7). For drug-eluting
absorbable magnesium scaffolds (DREAMS), the
vessel curvature decreased 40.5% post-implantation
(p < 0.01), but the difference between baseline and
12-month follow-up was reduced to 7.4% (p ¼ 0.03)
(8). This means that the BRS tended to restore the
coronary conﬁguration and systolodiastolic move-
ments to those seen before implantation, whereas the
coronary geometry remained similar to that seen after
implantation with MPS.
VASOMOTION. Vasomotor testing, using nitroglyc-
erin, methylergometrine (endothelium-independent
vasoconstrictor), and acetylcholine (Ach) (endothe-
lium-dependent vasoactive agent), can be performed
at various time points.
Vasomotion of the scaffolded segment following
intraluminal administration of Ach suggests that:
1) the scaffolding function of the struts has com-
pletely disappeared and the so-called scaffolded
segment can now exhibit vasomotion; 2) the endo-
thelial lining (coverage) is coalescent; 3) the ciliary
function of the endothelial cell is functional; and
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FIGURE 1 Angiographic Findings and Parameters for Bioresorbable Scaffold Assessment
(A) Time-related late lumen loss of bioresorbable vascular scaffolds (BRS) in clinical trials. (B) Angiographic parameters for bioresorbable scaffold
assessment. Immediately after scaffold implantation, there is an important luminal increase (acute gain); at follow-up, there could be either a reduction in
lumen size in comparison with the luminal size after implantation (late loss) or a further increase in lumen size (late gain). The latter is a unique angiographic
ﬁnding following the use of BRS.
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11334) the biochemical process through which nitric
oxide is released properly works. A positive Ach test
with vasodilation of the scaffold is indirect proof that
the endothelium is functional (9).
Mean lumen diameters in the scaffolded proximal
and distal segments are measured by QCA after a
baseline infusion of saline and subselective intra-
coronary administration of Ach, infused through a
microcatheter at increasing doses up to a maximum
of 106 M. In particular, a 2-min selective infusion of
Ach (108, 107, and 106 mol/l) is administrated
with a washout period of at least 5 min between
each dose (10). Nitrate (200 mg) is administrated
following Ach. Vasoconstriction to Ach is deﬁned asa 3% change in the mean lumen diameter, beyond
the variability of the method of analysis, after infu-
sion of the maximal dose of Ach (106 M), as previ-
ously shown.
In the Absorb scaffold, patients at 24 months (n ¼
8) exhibited, on average, a signiﬁcant increase in
the mean lumen diameter after Ach administration
compared with patients at 12 months [þ6.16 (1.07,
þ13.14) vs. 6.41% (11.74, 1.17); p ¼ 0.006] (11).
The timing of restored vasomotion after BRS is also
a surrogate for loss of structural integrity of the de-
vice and an indication when the vessel may respond
to normal and exercise-induced changes in coronary
blood ﬂow and pressure. For the Absorb scaffold, the
FIGURE 2 Absorb BRS
The metallic markers are mounted at the proximal and distal ends of the Absorb BRS
(Cohort B device, revision 1.1) (A, yellow arrow). These markers can be seen in cine
angiography, which represents the overlapping of 2 BRS (B, black arrow and double
arrow). In the cross-sectional images of intravascular ultrasound and optical coherence
tomography, the metallic markers can be identiﬁed as high echogenic and high light-
intensity structures accompanied by backward shadows, respectively (B, white arrows).
Abbreviation as in Figure 1.
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1134time seems to be 12 months; for the DREAMS scaffold,
the time seems to be 6 months (8).
NONINVASIVE QCA BY MSCT
Unlike any other metallic prosthesis, polymeric BRS
allow in-scaffold assessment of the coronary lumen
because the struts are radiolucent; the exception is
BRS made of tyrosine polycarbonate and iron,
which are radiopaque. Similarly to coronary angi-
ography, the only recognizable structures are the
metallic markers at both ends of the devices
(Figure 4). BRS technologies use radiopaque
markers that are made of platinum, gold, or
tantalum. These materials should not interfere with
angiographic assessments.
LATE LOSS/LATE LUMINAL GAIN. As mentioned
previously, MSCT provides QCA-like parameters, and
the same deﬁnitions are used.CONFORMABILITY. In MSCT, the center line of the
vessels can be precisely determined and both curva-
ture and angulation can be easily computed
(Figure 5). We compute the radius of the circum-
scribed circle through 3 sequential center-line co-
ordinates. The curvature at Pi is deﬁned as the
inverse of the radius of the circumscribed circle
around the 3 coordinates (Pa, Pi, and Pb), where Pa
and Pb are equally distant from Pi over a 4-mm
moving window at 0.1-mm intervals along the coro-
nary center line (12). Different than the curvature
measured in a ﬁxed 2D projection in angiography, this
curvature assessment in MSCT can be performed in a
3D reconstructed image.
NONINVASIVE FRACTIONAL FLOW RESERVE.
Computational ﬂuid dynamics, as applied to MSCT
images, is a novel method that enables prediction of
blood ﬂow and pressure ﬁelds in coronary arteries
and calculation of lesion-speciﬁc fractional ﬂow
reserve (FFR) (13–15). The FFR is computed from
commonly acquired MSCT scans (FFRCT) without any
modiﬁcation of MSCT protocols, additional image
acquisition, or administration of medications.
The FFRCT technology is based on 3 key princi-
ples. The ﬁrst is that coronary supply meets
myocardial demand at rest (total resting coronary
ﬂow is relative to ventricular mass). The second is
that resistance of the microcirculation at rest is
inversely but not linearly proportional to the size of
the feeding vessel. The third principle is that
microcirculation reacts predictably to maximal hy-
peremic conditions in patients with normal coro-
nary ﬂow. On the basis of these principles, a
lumped parameter model representing the resis-
tance to ﬂow during simulated hyperemia is applied
to each coronary branch of the segmented MSCT
model. The FFRCT is modeled for conditions of
adenosine-induced hyperemia; an FFRCT #0.80 is
considered diagnostic of lesion-speciﬁc ischemia
(Figures 6A and 6B) (16).
GRAY-SCALE INTRAVASCULAR
ULTRASOUND
Treated coronary vessels are examined after the
procedure and at follow-up with intravascular ultra-
sound (IVUS) catheters. The scaffolded segment and
its 5-mm distal and proximal segments are also
examined. The vessel area, scaffold area, lumen area,
intrascaffold neointimal area, and luminal area ste-
nosis are measured with a computer-based contour
detection program.
PERCENTAGE OF LUMEN AREA STENOSIS. The per-
centage of lumen area stenosis is calculated as
TABLE 3 Deﬁnitions and Formulas of Parameters for Assessment of BRS
Parameter Imaging Modality Formula Deﬁnition and Notes
Late loss/late luminal gain Angiography (QCA)/MSCT MLD (post-procedure) – MLD (follow-up) For a lumen diameter reduction, this will be a positive number; for a late
increase in lumen size, this will be a negative number
Acute recoil Angiography (QCA)/MSCT 1. Without post-dilation: mean diameter
(delivery balloon at the highest pressure)
 mean luminal diameter (after
implantation)
2. With post-dilation: mean diameter (post-
dilation balloon at the highest pressure) 
mean luminal diameter (after post-dilation)
Two speciﬁc views need to be analyzed: one is an image of complete
expansion of the last balloon (either the device delivery balloon or
the post-dilation balloon) at the highest pressure and the other is a
cine frame immediately after the last balloon deﬂation and
subsequent nitrate injection; these 2 images are analyzed in the
same angiographic projection selected to minimize foreshortening
Curvature Angiography (QCA)/MSCT 1/r (cm1) Deﬁned as the inﬁnitesimal rate of change in the tangent vector at each
point of the center line; this measurement has a reciprocal
relationship with the radius of the perfect circle deﬁned by the
curve at each point
Angulation Angiography (QCA)/MSCT Deﬁned as the angle in degrees that the tip of an intracoronary
guidewire would need to reach the distal part of a coronary bend
Vasomotion Angiography (QCA) 1. Vasoconstriction: D mean lumen diameter
(post-pre) #3%
2. Vasodilation: D mean lumen diameter
(post-pre) $3%
Vasoconstriction/vasodilation are deﬁned as at least 3% change in the
mean lumen diameter after infusion of the maximal dose of Ach/
nitrates, respectively
Noninvasive fractional ﬂow
reserve (FFRCT)
MSCT Computed by a dedicated program; FFRCT was modeled after conditions
of adenosine-induced hyperemia; FFRCT #0.80 is considered
diagnostic of lesion-speciﬁc ischemia
Lumen area stenosis Gray-scale IVUS/OCT ([Mean lumen area – minimum lumen area]/
mean lumen area)  100
Eccentricity index Gray-scale IVUS/OCT Minimum scaffold diameter/maximum
scaffold diameter in a frame
The average of all eccentricity indexes of each frame within a scaffolded
segment is calculated
Symmetry index Gray-scale IVUS/OCT (Minimum scaffold diameter  maximum
scaffold diameter)/maximum scaffold
diameter within a scaffolded segment
The maximum and the minimum stent/scaffold diameters in this
calculation are possibly located in 2 different frames over the length
of the device implanted
Neointima hyperplasia area Gray-scale IVUS Scaffold area – lumen area Applicable in frames where all struts are apposed
Percentage area
obstruction
Gray-scale IVUS Neointima hyperplasia area/scaffold area  100
Late recoil Gray-scale IVUS/OCT Scaffold area at post-procedure – scaffold
area at follow-up
Incomplete apposition/late
incomplete apposition
Gray-scale IVUS/OCT Deﬁned as 1 or more scaffold struts separated from the vessel wall;
acquired late incomplete apposition is deﬁned as incomplete
apposition at follow-up that is not present after the procedure
Compositional area Virtual histology Necrotic core, dense calcium, ﬁbrofatty, and ﬁbrous areas are analyzed;
polymeric struts are usually recognized as dense calcium
Compositional area iMap Fibrotic, lipidic, necrotic, and calciﬁed tissues are analyzed
Compositional area IB-IVUS Lipid, ﬁbrous, dense ﬁbrous, and calciﬁed tissues are analyzed
Strain value Palpography Radiofrequency data obtained at different pressure levels are compared
to determine local tissue deformation; strain value is normalized to
a pressure difference of 2.5 mm Hg per frame, which allows the
construction of a “strain” image in which hard (low strain/
compliance) and soft (high strain/compliance) values range
between 0% and 2%
Scaffold area OCT At baseline, the scaffold area is measured by joining the middle point of
the black core abluminal side of the apposed struts or the abluminal
edge of the frame borders of malapposed struts; at follow-up, the
back (abluminal) side of the central black core has been used to
delimit the scaffold area
Blood ﬂow area OCT (Scaffold area þ ISA area) – (intraluminal
strut areas þ prolapse area þ intraluminal
defect)
Neointimal hyperplasia
area
OCT 1. When all struts are apposed: scaffold area –
(lumen area þ black box area)
2. When malapposed struts: (scaffold areaþ ISA
area þ malapposed strut with surrounding
tissues) – (lumen area þ strut area)
Note the difference in methodology versus that of gray-scale IVUS
Thickness of tissue
coverage
OCT Distance between the abluminal site of the
strut and the lumen – strut thickness
Ach ¼ acetylcholine; ISA ¼ incomplete stent apposition; IB ¼ integrated backscattered; IVUS ¼ intravascular ultrasound; MLD ¼ minimal lumen diameter; MSCT ¼ multislice coronary tomography;
OCT ¼ optical coherence tomography; QCA ¼ quantitative coronary angiography; other abbreviation as in Table 1.
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FIGURE 3 Curvature and Angulation Analyses
Curvature (A) and angulation (B) analyses are shown before deployment (A1 and B1) and after deployment (A2 and B2). Curvature is estimated as 1/radius
(0.203 mm1 in A1 and 0.148 mm1 in A2). Angulation is deﬁned by the tangents of the center lines (6). BVS tends to allow restoration of the coronary
geometry and systo-diastolic movements of the coronary arteries similar to that seen before implantation (C1 to C3). Modiﬁed with permission from Gomez-
Lara et al. (7).
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1136100 times the mean lumen cross-sectional area
minus the minimal lumen area divided by the mean
lumen cross-sectional area within the scaffolded
segment.
ECCENTRICITY AND SYMMETRY. The eccentricity
and symmetry, easily detectable by IVUS, havepreviously been demonstrated to be related to either
favorable or adverse clinical outcomes (17,18). With
the transition from a metallic stent to a polymeric
bioresorbable platform, re-evaluation of these geo-
metric parameters is required at short- and long-term
follow-ups.
FIGURE 4 Multislice Coronary Tomography
Multislice coronary tomography (MSCT) shows the radio-opaque markers visible in the scaffolded vessel (A). The radio-opaque markers appear
much larger (arrows) than the actual size because of an artefact (i.e., blooming effect) due to partial volume averaging which is typical of highly
radio-opaque objects that are imaged by MSCT (B). (C) shows a comparison of lumen assessment by MSCT for a bioresorbable scaffold (green
arrows), an overlap scaffold-metallic stent (yellow arrow), and a metallic stent (red arrow).
FIGURE 5 Curvature
(A) Method to calculate vessel curvature. A window size of the vessel diameter was moved down along the center-line path incrementally to
identify 3 adjacent points on the center-line path for the curvature calculation. In MSCT, curvature is computed as the inverse of the radius of a
circumscribed circle over a 4-mm moving window at 0.1-mm intervals along the left anterior descending artery center line (B). Modiﬁed with
permission from Choi et al. (12).
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FIGURE 6 Principles of Fractional Flow Reserve
Standard coronary computed tomography angiography data are obtained. (A) Five-year results following an Absorb implantation are shown.
Arrowheads indicate the 2 metallic markers in the left anterior descending artery. Noncalciﬁed plaque results in 62% area stenosis. (B) A
quantitative 3-dimensional anatomic model is generated. (C) A physiological model of the coronary microcirculation is derived from patient-
speciﬁc data with 3 main principles: 1) resting coronary ﬂow proportional to myocardial mass; 2) microvascular resistance inversely proportional
to vessel size; and 3) microvascular resistance reduced to simulate maximal hyperemia. (D) Physical laws of ﬂuid dynamics are applied to
compute coronary blood ﬂow. (E) Fractional ﬂow reserve (FFRCT) is calculated throughout the coronary arteries. (F) From the proximal to the
distal edge of the scaffold, the FFRCT decreases from 0.88 to 0.80. Modiﬁed with permission from Onuma et al. (46), Norgaard et al. (47), and
Nieman et al. (48).
Garcia-Garcia et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 1 , 2 0 1 4
Assessing Bioresorbable Coronary Devices N O V E M B E R 2 0 1 4 : 1 1 3 0 – 4 8
1138Eccentricity index is deﬁned as the ratio of the
minimum and maximum diameters in each frame;
thereafter, the average of all eccentricity indexes
is calculated. Symmetry index is calculated as
(maximum stent/scaffold diameter in a single frame 
minimum stent/scaffold diameter in a single frame)
divided by the maximum stent/scaffold diameter.
Note that the maximum and minimum stent/scaffold
diameters in this calculation are possibly located in
2 different frames over the length of the device
implanted (Figure 7).
NEOINTIMA HYPERPLASIA. Assessment of the neo-
intima hyperplasia by IVUS is in principle similar to
the methodology used for metallic devices. Neo-
intimal hyperplasia area is deﬁned as scaffold area
minus lumen area if all struts are apposed. Percentagevolume obstruction is deﬁned as neointima hyper-
plasia volume divided by scaffold volume.
LATE RECOIL. Although “late recoil” has been used
frequently in interventional cardiology to describe
the constrictive remodeling of the external elastic
membrane area, here it relates more speciﬁcally to
the area reduction of the scaffolded segment, a phe-
nomenon not previously observed in metallic stents.
Attributed to the early alteration of the mechanical
integrity of the scaffold, this phenomenon can be
controlled by polymer processing.
Late absolute stent recoil is deﬁned as stent area at
post-procedure (X)  stent area at follow-up (Y). Late
percent stent recoil was deﬁned as (X  Y)/X  100.
The assessment of late recoil helped to clarify
the reasons for the suboptimal performance of the
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1139ﬁrst-generation magnesium scaffold. For the AMS-1
(Biotronik, Bülach, Switzerland), this parameter was
responsible for 42% of luminal obstruction due to its
rapid scaffold degradation and led to its design
modiﬁcation (19,20).
Late absolute and percent recoil of the Absorb BVS
1.0 was 0.65  1.71 mm2 (95% conﬁdence interval:
0.49 to 0.80 mm2) and 7.60  23.3% (95% conﬁdence
interval: 5.52% to 9.68%) (21). With the newer itera-
tion of the device, BVS 1.1, the mean scaffold
area increased from baseline to 3 years by IVUS
(6.3 to 7.1 mm2) and by optical coherence tomography
(OCT) (7.8 to 8.6 mm2) (22). Similarly, the DESolve Nx
BRS showed an increase in mean scaffold area by
IVUS (5.4 to 5.6 mm2) and OCT (6.6 to 6.8 mm2) (4).
INCOMPLETE APPOSITION. Incomplete apposition is
deﬁned as 1 or more scaffold struts separated from
the vessel wall; acquired late incomplete apposition is
deﬁned as incomplete apposition at follow-up that is
not present after the procedure.
With BVS 1.1 at baseline, 4 patients showed
incomplete stent apposition (ISA). One ISA persistedMinimum and maximum
diameters through the
gravitational center
of the lumen
Cross sections of the device with the
minimum and maximum diameters (D)
through the gravitational center of the lumen,
showing different eccentricity indices
3.1 mm
1.9 mm
3.1 mm
2.5 mm
2.7
2.7 mm
Intracoronary devi
FIGURE 7 Relationship Between the Symmetry and Eccentricity Ind
Minimum and maximum diameters over the length of the device are sho
shown. Modiﬁed with permission from Brugaletta et al. (49).at follow-up, and 3 ISAs resolved. At 6 months’
follow-up, 3 patients developed a late acquired ISA
(23). In the other group followed up to 1 year, at
baseline, there were 5 patients with ISA and at
follow-up there were only 4 (24). At 2 years, incom-
plete apposition by IVUS was only observed in 2 pa-
tients. At 3 years, 3 patients presented late acquired
malapposition (22). The DESolve Nx BRS resulted
in only 1 patient with malapposition at 6 months by
OCT (4).
EDGE EFFECTS. The edge effect was ﬁrst introduced
in the era of endovascular brachytherapy using
radioactive stents of various activity levels to
describe tissue proliferation at the nonirradiated
proximal and distal edges and resulted in the failure
of this invasive treatment. The advent of ﬁrst- and
second-generation drug-eluting stents (DES) reduced
in-stent restenosis to approximately 5% to 10%
depending on the lesion subset and type of DES.
When in-segment restenosis (stent and 5-mm prox-
imal and distal margins) occurred, it was most
commonly focal and located at the proximal edge.Center of the lumen
 mm
ce Vessel wall
Eccentricity Index = = = 0.92
Min D per frame
Max D per frame
2.5
2.7
Symmetry Index = = = 0.13
[max D – min D]
Max D
[3.1 – 2.7]
3.1
exes of an Intracoronary Device
wn. Two cross-sections with different eccentricity indexes are also
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1140The ABSORB Cohort B trial enrolled 101 patients
and was divided into B1 (n ¼ 45) and B2 (n ¼ 56)
subgroups. The adjacent (5-mm) proximal and distal
vessel segments to the implanted Absorb BVS were
investigated at either 6 months (B1) or 1 year (B2) with
intravascular ultrasound-virtual histology (IVUS-VH)
imaging.
At the 5-mm proximal edge, the only signiﬁcant
change was modest constrictive remodeling at
6 months (change in vessel cross-sectional area:
1.80% [3.18%; 1.30%]; p < 0.05), with a tendency
to regress at 1 year (change in vessel cross-sectional
area: 1.53% [7.74%; 2.48%]; p ¼ 0.06). The rela-
tive changes in the ﬁbrotic and ﬁbrofatty (FF) tissue
areas at this segment were not statistically signiﬁcant
at either time point. At the 5-mm distal edge, a
signiﬁcant increase in the FF tissue areas of
43.32% (19.90%; 244.28%; p < 0.05) 1 year post-
implantation was evident. Changes were also
observed in dense calcium areas, which need to be
interpreted with caution. The polymeric struts are
detected as “pseudo” dense calcium structures with
the IVUS-VH imaging modality, and the edges of the
polymeric scaffold are not sharply demarcated
because the vessel surrounding the imaging device
are affected by the “to and fro” motion of the cardiacFIGURE 8 Comparison Between Imaging Techniques in Detecting th
After implantation, the polymeric struts are seen as open boxes in optica
gray-scale intravascular ultrasound (IVUS) (at 4 and 7 to 8 o’clock). The c
calcium), whereas echogenicity shows them in green (hyperechogenic). N
tissue) into the vessel wall. Gray-scale IVUS shows that the strut at 4 o
echogenicity are also not detected. These latter observations reﬂect somcontraction, causing a longitudinal displacement of
the IVUS catheter relative to the arterial wall (25).
VIRTUAL HISTOLOGY
Ultrasound backscattered signals are acquired using
either a 20-MHz (electronic) or 45-MHz (mechanical)
IVUS catheter. Backscattering of radiofrequency sig-
nals provides information on vessel wall tissue
composition. Four tissue components (necrotic core
[red], dense calcium [white], ﬁbrous, [green], and FF
[light green]) are identiﬁed with autoregressive clas-
siﬁcation systems and expressed as percentages per
cross-section (necrotic core, dense calcium, FF, and
ﬁbrous) (26). In each cross-section, polymeric scaffold
struts are detected as areas of apparent dense calcium
and necrotic core resulting from the strong back-
scattering properties of the polymer. We use the
change in quantitative analyses of these areas be-
tween implantation and follow-up as a surrogate
assessment of the chemical and structural alterations
of the polymeric struts (Figure 8). The recent an-
alysis of the ABSORB Cohort B study showed that the
mean dense calcium areas were 29.84 mm2 (post-
implantation), 28.16 mm2 (6 months), 24.25 mm2
(1 year), 27.74 mm2 (2 years), and 21.52 mm2 (3-yeare Degradation Parameters in Matched Frames
l coherence tomography (OCT), whereas they are white structures in
olor-coded virtual histology (VH) image depicts them in white (dense
ote that at follow-up, OCT shows all struts integrated (covered with
’clock is less apparent, whereas the corresponding ones in VH and
e biodegradation.
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1141follow-up). The average necrotic core areas, at the
same aforementioned time points, were 31.31 mm2,
30.11 mm2, 30 mm2, 31.67 mm2, and 26.49 mm2,
respectively. The sharp decrease in dense calcium
and necrotic core areas between 24 and 36 months
may also reﬂect the end of the inﬂammatory process,
with regression of the plaque behind the struts (22).
In addition, the other critical observation with
IVUS between the 6-month and 2-year follow-ups was
a late luminal enlargement (10.9%) with signiﬁcant
plaque media reduction (12.7%) and without signiﬁ-
cant change in the vessel wall area (27). It is still
unknown whether this “plaque media regression” on
IVUS is a true atherosclerotic regression, with change
in vessel wall composition and plaque morphology
(from thin-cap atheroma to thick-cap atheroma) or a
pseudo-regression due to bioresorption of the poly-
meric struts. True atherosclerotic regression could
only be hypothesized based on animal and in vitro
experiments showing that mammalian target of
rapamycin can trigger a complex chain of biological
reactions that lead ﬁnally to activation of genes
related to autophagy of macrophages. Systemic
application of everolimus decreased atherosclerotic
plaque formation in low-density lipoprotein receptor
knockout mice (28).
IMAP
Ultrasound backscattered signals are acquired using
a 40-MHz mechanically rotating IVUS catheter. iMap
is another radiofrequency-based processing method
for coronary plaque tissue characterization (29). iMap
uses a pattern recognition algorithm on the spectra
that were obtained from a fast Fourier transformation
and a histology-derived database (29). The color code
for tissue types is different than that for IVUS-VH.
iMap depicts ﬁbrotic (light green), lipidic (yellow),
necrotic (pink), and calciﬁed (blue) tissues, whereas
IVUS-VH depicts ﬁbrous (green), FF (yellow-green),
necrotic core (red), and dense calcium (white) tis-
sues (30). Although iMap has been validated for
characterization of stents/scaffolds, we have
observed that it detects polymeric struts as calciﬁed
tissue (Figure 9); however, it misses some of the
polymeric struts, which makes this technology not
suitable to serially follow the absorption process of
these polymeric scaffolds.
INTEGRATED BACKSCATTERED IVUS
Ultrasound backscattered signals are acquired using
a 40-MHz mechanically rotating IVUS catheter.
Integrated backscattered values for each tissuecomponent were calculated as an average power
using a fast Fourier transformation, measured in
decibels, of the frequency component of the back-
scattered signal from a small volume of tissue. With
predeﬁned ranges of integrated backscattered values,
each plaque component is characterized as lipid
(blue), ﬁbrous (green), dense ﬁbrous (yellow), or
calciﬁed (red) tissue (Figure 9) (31,32).
PALPOGRAPHY
Percutaneous implantation of metallic prostheses has
been used to alleviate ﬂow-limiting lesions by over-
stretching the plaque and the underlying vessel wall.
From a mechanical perspective, this treatment may
locally stiffen the artery, reducing its compliance and
creating a mismatch in compliance with respect to the
segments contiguous to the implanted device (5).
This mismatch may eventually provoke ﬂow distur-
bances and wall shear stress alterations, with subse-
quent blood stasis. The wall shear stress distribution
in a stented artery has been reported as a determinant
factor for cellular growth and thrombus formation.
The Absorb everolimus-eluting BVS theoretically has
many advantages compared with rigid metallic
stents. In particular, because the scaffold is made
completely of polylactide, it does not have the
same stiffness as metal, thereby having the potential
to overcome in part the problems related to local
stiffening of the artery and compliance mismatch
associated with MPS. In addition, the mismatch in
compliance after scaffold implantation may poten-
tially disappear in the long term once the scaffold is
completely bioresorbed.
IVUS palpography is a technique that allows for
the assessment of local mechanical tissue properties.
The underlying principle is that at deﬁned pressure,
differences in soft-tissue (e.g., lipid-rich) compo-
nents deform more than hard-tissue components
(e.g., ﬁbrous calciﬁed) (33). In coronary arteries, the
tissue of interest is the vessel wall, whereas the
blood pressure, with its physiological changes during
the heart cycle, is used as the excitation force.
Radiofrequency data obtained at different pressure
levels are compared to determine local tissue
deformation. The strain value is normalized to a
pressure difference of 2.5 mm Hg per frame; this
allows the construction of a “strain” image in which
hard (low strain/compliance) and soft (high strain/
compliance) values range between 0% and 2%. In
post-mortem coronary arteries, the sensitivity and
speciﬁcity of palpography to detect high strain
values have previously been reported as 88% and
89%, respectively (34).
FIGURE 9 Newly Implanted Polymeric Scaffold
The newly implanted appearance of a polymeric scaffold in gray-scale IVUS (A) and color-coded iMap (B). Solid arrows point at polymeric struts
characterized as calcium, whereas dotted arrows in gray-scale IVUS (B) are pointing at polymeric struts, which are not characterized as calcium
by iMap (B). (C) Gray-scale IVUS image of a polymeric scaffold inside a phantom. (D) Corresponding color-coded integrated backscattered
IVUS. The polymeric struts are classiﬁed as calcium (red). Abbreviation as in Figure 8.
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1142Local strain is calculated from the gated radio-
frequency traces using cross-correlation analyses,
displayed and color-coded from blue (for 0% strain)
to yellow (for 2% strain) via red, as previously
described.
Strain values were assigned a Rotterdam classiﬁ-
cation (ROC) score ranging from I to IV (ROC I 0 to
0.5%; ROC II 0.6% to <0.9%; ROC III 0.9% to 1.2%;
and ROC IV >1.2%). A region was deﬁned as a
high-strain spot when it had high strain (ROC III to IV)
that spanned an arc of at least 12 at the surface of a
plaque (identiﬁed on the IVUS recording) adjacent to
low-strain regions (<0.5%), as previously reported
(33). The highest value of strain in the cross-sectionwas taken as the strain level of the spot. The
compliance of each segment is calculated per
segment (proximal edge, scaffold segment, and distal
edge) and deﬁned as the mean of the maximum strain
values per cross-section in ROC I/II/III/IV spots,
expressed as ROC/mm.
ECHOGENICITY
Echogenicity uses the gray-scale IVUS data to
further evaluate the distribution of the gray values
within a speciﬁc coronary segment. The mean
gray value of the adventitia is used to classify
tissue components as either hypoechogenic or
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1143hyperechogenic (Figure 8). The adventitia sur-
rounding the coronary artery is deﬁned as a layer
extending from 0.2 to 0.5 mm outside the external
elastic membrane. To avoid artifacts, tissue within
acoustic shadowed areas is excluded and very high
gray-level pixels are identiﬁed as upper tissue. After
the tissue identiﬁcation process, the relative frac-
tion of hypoechogenic versus hyperechogenic tissue
volumes is calculated for the entire scaffolded
segment. The software calculates the echogenicity
as a volume and percentage for each scaffolded
segment (setting hypoechogenicity and hyper-
echogenicity to 100%). The percent differential
echogenicity was calculated for each scaffolded
coronary segment, as follows (35,36).
%DifferentialEchogenicity ¼
ð%Hyper6M%HyperPreÞð%HyperPost%HyperPreÞ
ð%HyperPost%HyperPreÞ
,100%
Echogenicity parameters have been shown to be
able to detect temporal changes in the gray-level in-
tensities for Absorb and DREAMS, being putatively
correlated to scaffold degradation over time (8,35).FIGURE 10 Newly Implanted BRS
(A)Metallic stent approach: lumen area 10.16 mm2; stent area 7.84 mm2 (incomplete stent
apposition [ISA] 2.32 mm2). (B) BRS approach: lumen area 10.16 mm2; stent area 9.58 mm2
(ISA 0.58 mm2). (C) Additional analysis: strut area 0.61 mm2; blood ﬂow area (lumen area –
strut area) 9.55 mm2. (D) Follow-up. The strut (core) area is deﬁned only by its black core
because the light-scattering frame is no longer distinguishable from surrounding tissue.
Abbreviation as in Figure 1.OPTICAL COHERENCE TOMOGRAPHY
The BVS presents important differences with respect
to metallic stents when imaged by OCT. The optically
translucent polymeric struts appear as black central
cores framed by light-scattering borders that do not
shadow the vessel wall and allow complete imaging
of the strut thickness. The main quantitative mea-
surements (strut core area, strut area, lumen area,
scaffold area, ISA area, and neointimal area) require
different analysis rules than the metallic stents
(Figure 10).
Qualitatively, the diagnosis of acute strut fracture
resulting from balloon overdilation or late structural
strut discontinuity can be established if 2 struts
overhang each other in the same angular sector of the
lumen perimeter, with or without malapposition, or if
isolated struts are located more or less at the center of
the vessel without obvious connection to other sur-
rounding struts in 2D OCT. For conﬁrmation of the
diagnosis, it is helpful to perform 3D OCT recon-
struction of the disrupted strut. A case description of
strut fracture is shown in Figure 11.
At baseline, the strut area is imaged as a central
black core and a light-scattering frame border. How-
ever, at follow-up, embedding, coverage, and thick-
ening of the frame borders, with apparent reduction
of the central core, render the analysis of the strutsmore complex. At this time point, the strut (core) area
is deﬁned only by its black core because the light-
scattering frame is no longer distinguishable from
surrounding tissue. At follow-up, the strut area starts
to gain some tissue ﬁlling that can be seen as “white
core” (Figure 12).
The lumen and scaffold contours are obtained with
a semiautomated detection algorithm available in
many ofﬂine software packages, and additional
manual corrections are performed if necessary. At
baseline, because the polymeric struts are trans-
lucent, the vessel wall lumen area can be imaged
and delineated at the back (abluminal) side of the
struts. At follow-up, the luminal area is drawn by
FIGURE 11 Bioresorbable Scaffold Discontinuity
A 59-year-old man with treated hypercholesterolemia as his only cardiovascular risk factor was admitted to the hospital with stable angina. The coronary
angiogram revealed a stenotic lesion in the mid left anterior descending coronary artery. As protocol mandated, pre-dilation was performed with a single
inﬂation of a 2.5  12 mm Voyager balloon (Abbott Laboratories, Abbott Park, Illinois) at 10 atm, followed by implantation of a 3.0  18.0 mm bioresorbable
everolimus-eluting scaffold at 10 atm. A post-dilation was performed with a 3.25  15.0 mm Voyager balloon at 20 atm (expected balloon diameter
3.41 mm). The patient continued to be asymptomatic up to 6 months when he visited the hospital for a re-catheterization because he was enrolled in a
clinical study. By a 2-dimensional (cross-sectional) OCT image, an extreme malapposition of 1 strut was observed (B, yellow arrow). In a 3-dimensional OCT
reconstruction, the overhanging strut was clearly identiﬁed in its whole trajectory (C and D, yellow arrow). This patient was left untreated due to lack of
ischemic symptoms. Abbreviation as in Figure 8.
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1144semiautomatic detection, following the endoluminal
contour of the neointima between and on top of the
apposed struts. For malapposed struts, the endolu-
minal contour of the vessel wall behind the malap-
posed struts is used.
At baseline, the scaffold area is measured by
joining the middle point of the black core abluminal
side of the apposed struts or the abluminal edge ofthe frame borders of malapposed struts. The scaffold
area is identical to the lumen area in the absence of
ISA and prolapse. At follow-up, the back (abluminal)
side of the central black core is used to delimit the
scaffold area. Three different situations deserve spe-
cial consideration. First, incomplete strut apposition
is deﬁned as a clear separation between the back
(abluminal) side of the strut and the vessel wall. For
FIGURE 12 Optical Coherence Tomography Light Intensity Analysis
Corresponding OCT cross-sections (red asterisks indicate distal metallic markers) at 1 and 3 years. The strut next to the marker (asterisk) was
analyzed by light reﬂectivity. At 3 years, the strut core was partially ﬁlled by a white nucleus exhibiting high light reﬂectivity. Tracings at the
bottom showed graphically the light reﬂectivity along the scan line of incident light (red). The vertical green dotted lines correspond to the
adluminal and abluminal boundaries of the black core either empty or partially occupied by white nucleus. Histological image (Movat staining,
20) of porcine coronary artery 36 months after implantation of Absorb scaffold shows provisional matrix (glycoconjugates) in purple, ﬁlling
the void previously occupied by the polymeric strut. A cellularized (black dot) area with connective tissue (green) is located at the center of the
strut void and is connected by a peduncle to the subintima. Multiple layers of smooth muscle cells are overlying the strut voids. OCT images of
the histological structures in a porcine model are very similar to those observed in humans. The light intensity was analyzed using open-source
software (ImageJ, National Institutes of Health, Bethesda, Maryland). Modiﬁed with permission from Serruys et al. (22).
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1145malapposed struts, incomplete strut apposition area
is delineated by the abluminal side of the frame
border of the malapposed strut (covered or uncov-
ered) and the endoluminal contour of the vessel wall.
Second, in prolapse protruding between struts into
the lumen at baseline, the prolapse area can be esti-
mated between the prolapsed contour (lumen con-
tour) and the scaffold area. Third, an intraluminal
defect free from the vessel wall (e.g., thrombus) is
also quantiﬁed as an area. According to these ﬁnd-
ings, the ﬂow area is deﬁned as (scaffold area þ ISA
area)  (intraluminal strut areas þ prolapse area þ
intraluminal defect).Neointimal hyperplasia area is deﬁned as (scaffold
area  [lumen area þ black box area]) if all struts are
apposed (Figure 10D), whereas it is calculated as
([scaffold area þ ISA area þ malapposed strut with
surrounding tissues] – [Lumen area þ strut area]) for
malapposed struts.
The thickness of the coverage is measured in every
strut between the abluminal site of the strut core and
the lumen. Because the strut thickness is 150 mm, the
strut is considered covered whenever the thickness of
the coverage is above this threshold value. This
method may slightly underestimate the thickness of
the coverage because it does not take into account
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1146changes in the size of the strut core over time.
Consequently, the percentage of uncovered struts
may be slightly overestimated.
This OCT Healing Score is a weighted index that
combines the following parameters (37):
1. Presence of intrastent structure (ISS) is assigned a
weight of “4.”
2. Presence of both malapposed and uncovered struts
(%MU) is assigned a weight of “3.”
3. Presence of uncovered struts alone (%U) is
assigned a weight of “2.”
4. Presence of malapposition alone (%M) is assigned a
weight of “1.”Neointimal Healing Score ¼
ðISS 4Þ þ ð%MU 3Þ þ ð%U 2Þ þ ð%M 1Þ
LESSONS FROM OCT FOR BRS RESORPTION. OCT
may not be sensitive enough to assess the resorption
process of the polymer, but it provides critical infor-
mation on the integration of the polymer into the
vessel wall. At the beginning, the absence of strut
footprints on OCT was interpreted as a sign of com-
plete bioresorption, but now we know that the pre-
served box appearance with optical translucency is
compatible with complete polymer dissolution (38).
The DESolve Nx BRS showed signiﬁcant reduction in
the number of struts with the black box appearance at
6 months (4).
TWO-DIMENSIONAL VERSUS 3-DIMENSIONAL OCT.
Three-dimensional OCT provides much more useful
information at bifurcations and overlapping segments
than 2D OCT. Indeed, 3D OCT enables a detailed
assessment of both the longitudinal and cross-
sectional relationship between the jailed side
branches oriﬁce and the overhanging struts (39). Se-
rial 3D OCT also provides information about anatomic
modiﬁcations such as the presence of neointimal
bridges, which usually appear as an extension of the
pre-existing carina. From the quantitative point of
view, using 3D OCT reconstructed models, one can
assess the changes over time in the number of com-
partments and their geometric areas.
Three-dimensional OCT offers a unique opportu-
nity to observe the modiﬁcations of the shape of the
struts after side branch dilation.
In the overlapping regions, 2D OCT helps to iden-
tify single or stacked struts (inner vs. outer) and
stacked strut clusters (Figure 2). Lumen area is drawn
in nonoverlapping segments, and the following con-
siderations should be made for the scaffold area: it is
drawn from the abluminal side of the black core areaof the outermost strut or stacked strut cluster (where
all of the struts appose the vessel endothelium)
apposing the vessel wall. Where there does not
appear to be any apposition of a single strut or
stacked strut cluster to the vessel endothelium, the
contour of the scaffold area continues to follow the
outermost (most abluminal) scaffold strut or stacked
strut cluster. Three-dimensional OCT of overlapping
regions also helps us to assess the type of over-
lapping: interdigitating struts versus complete over-
lap (40,41).
AGREEMENT OF QCA, IVUS, AND OCT
FOR ASSESSMENT OF BRS
For scaffold length measurement, QCA has shown a
typical systematic bias: variable underestimation of
length but consistent underestimation of the same
magnitude at the index procedure and at follow-up,
eventually due to the effect of foreshortening. OCT
is the most accurate technique for measuring scaffold
length, whereas solid-state IVUS presents a random
error, mostly due to lack of smooth and continuous
pullback; therefore, volumetric analysis is not reli-
able. There is poor agreement for minimal lumen area
estimation between all of the imaging modalities
studied, including IVUS-OCT; hence, their values are
not interchangeable (42).
IVUS, due to its limited resolution, is unable to
detect incomplete malapposition and struts at side
branches compared with OCT. IVUS also has poor
reproducibility for the assessment of these 2 vari-
ables, whereas OCT has excellent assessment (43).
CONCLUSIONS
The upcoming bioresorbable era requires new imag-
ing modalities, parameters, and methodologies for
the longitudinal assessment of BRS. One of the man-
ifested characteristics of BRS is bioresorption of the
polymeric struts into the arterial wall. Although
proper validation with VH, echogenicity, and pal-
pography to evaluate this phenomenon has been
lacking, other observations with OCT and histology
have demonstrated convincing results. We intro-
duced a detailed description of the parameters
and methodologies for the assessment of BRS that
should be needed in the future longitudinal studies.
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